Clinical evaluation of the need for carbapenems to treat community-acquired and healthcare-associated pneumonia

Journal of Infection and Chemotherapy

Volumn 21, Issue 8, 2015, Pages 596-603

  Kamata, Kazuhiro ^a   Suzuki, Hiromichi ^a   Kanemoto, Koji ^a   Tokuda, Yasuharu ^b   Shiotani, Seiji ^a   Hirose, Yumi ^a   Suzuki, Masatsune ^a   Ishikawa, Hiroichi ^a  

^a TSUKUBA MEDICAL CENTER HOSPITAL   (Japan)

^b KYUSHU HOSPITAL   (Japan)

Author keywords

Antimicrobial stewardship; Carbapenem; Community acquired pneumonia; Healthcare associated pneumonia

Indexed keywords

BETA LACTAM; BIAPENEM; CARBAPENEM DERIVATIVE; DORIPENEM; HYPERTENSIVE AGENT; MACROLIDE; MEROPENEM; PANIPENEM PLUS BETAMIPRON; PIPERACILLIN PLUS TAZOBACTAM; QUINOLONE DERIVATIVE; SULTAMICILLIN; ANTIINFECTIVE AGENT; PENICILLANIC ACID; PIPERACILLIN; PIPERACILLIN, TAZOBACTAM DRUG COMBINATION;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; ARTIFICIAL VENTILATION; CAUSE OF DEATH; CLINICAL ASSESSMENT; CLINICAL EVALUATION; COMMUNITY ACQUIRED PNEUMONIA; COMPARATIVE STUDY; DISEASE SEVERITY; DYSPHAGIA; ENTERIC FEEDING; FEMALE; HAEMOPHILUS INFLUENZAE; HEALTH CARE ASSOCIATED PNEUMONIA; HUMAN; INTENSIVE CARE UNIT; KLEBSIELLA PNEUMONIAE; LEGIONELLA PNEUMOPHILA; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MORAXELLA CATARRHALIS; MORTALITY; MYCOPLASMA PNEUMONIAE; OUTCOME ASSESSMENT; PROGNOSIS; PSEUDOMONAS AERUGINOSA; STREPTOCOCCUS PNEUMONIAE; ANALOGS AND DERIVATIVES; COMMUNITY-ACQUIRED INFECTIONS; CROSS INFECTION; HOSPITAL MORTALITY; MICROBIOLOGY; MIDDLE AGED; NEEDS ASSESSMENT; PNEUMONIA, BACTERIAL; POLICY; PSEUDOMONAS INFECTIONS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CARBAPENEMS; COMMUNITY-ACQUIRED INFECTIONS; CROSS INFECTION; FEMALE; HOSPITAL MORTALITY; HUMANS; MALE; MIDDLE AGED; NEEDS ASSESSMENT; ORGANIZATIONAL POLICY; PENICILLANIC ACID; PIPERACILLIN; PNEUMONIA, BACTERIAL; PROGNOSIS; PSEUDOMONAS INFECTIONS;

EID: 84937630940     PISSN: 1341321X     EISSN: 14377780     Source Type: Journal    
DOI: 10.1016/j.jiac.2015.05.002     Document Type: Article

References (40)

1. Kahan J.S., Kahan F.M., Goegelman R., Currie S.A., Jackson M., Stapley E.O., et al. Thienamycin, a new beta-lactam antibiotic. I. Discovery, taxonomy, isolation and physical properties. JAntibiot (Tokyo) 1979, 32:1-12.
2. Kahan F.M., Kropp H., Sundelof J.G., Birnbaum J. Thienamycin: development of imipenen-cilastatin. JAntimicrob Chemother 1983, 12(Suppl D):1-35.
3. Papp-Wallace K.M., Endimiani A., Taracila M.A., Bonomo R.A. Carbapenems: past, present, and future. Antimicrob Agents Chemother 2011, 55:4943-4960.
4. Van Boeckel T.P., Gandra S., Ashok A., Caudron Q., Grenfell B.T., Levin S.A., et al. Global antibiotic consumption 2000 to 2010: an analysis of national pharmaceutical sales data. Lancet Infect Dis 2014, 14:742-750.
5. Luyt C.E., Aubry A., Lu Q., Micaelo M., Brechot N., Brossier F., et al. Imipenem, meropenem, or doripenem to treat patients with Pseudomonas aeruginosa ventilator-associated pneumonia. Antimicrob Agents Chemother 2014, 58:1372-1380.
6. Shindo Y., Ito R., Kobayashi D., Ando M., Ichikawa M., Shiraki A., et al. Risk factors for drug-resistant pathogens in community-acquired and healthcare-associated pneumonia. Am J Respir Crit Care Med 2013, 188:985-995.
7. Musher D.M., Roig I.L., Cazares G., Stager C.E., Logan N., Safar H. Can an etiologic agent be identified in adults who are hospitalized for community-acquired pneumonia: results of a one-year study. JInfect 2013, 67:11-18.
8. Maruyama T., Fujisawa T., Okuno M., Toyoshima H., Tsutsui K., Maeda H., et al. Anew strategy for healthcare-associated pneumonia: a 2-year prospective multicenter cohort study using risk factors for multidrug-resistant pathogens to select initial empiric therapy. Clin Infect Dis 2013, 57:1373-1383.
9. Saito A., Kohno S., Matsushima T., Watanabe A., Oizumi K., Yamaguchi K., et al. Prospective multicenter study of the causative organisms of community-acquired pneumonia in adults in Japan. JInfect Chemother 2006, 12:63-69.
10. Wunderink R.G., Waterer G.W. Clinical practice. Community-acquired pneumonia. NEngl J Med 2014, 370:543-551.
11. Suzuki H., Senda J., Yamashita K., Tokuda Y., Kanesaka Y., Kotaki N., et al. Impact of intensive infection control team activities on the acquisition of methicillin-resistant Staphylococcus aureus, drug-resistant Pseudomonas aeruginosa and the incidence of Clostridium difficile-associated disease. JInfect Chemother 2013, 19:1047-1052.
12. Hirshberg B., Sklair-Levi M., Nir-Paz R., Ben-Sira L., Krivoruk V., Kramer M.R. Factors predicting mortality of patients with lung abscess. Chest 1999, 115:746-750.
13. Ahmed R.A., Marrie T.J., Huang J.Q. Thoracic empyema in patients with community-acquired pneumonia. Am J Med 2006, 119:877-883.
14. Burgos J., Lujan M., Falco V., Sanchez A., Puig M., Borrego A., et al. The spectrum of pneumococcal empyema in adults in the early 21st century. Clin Infect Dis 2011, 53:254-261.
15. Shindo Y., Sato S., Maruyama E., Ohashi T., Ogawa M., Imaizumi K., et al. Comparison of severity scoring systems A-DROP and CURB-65 for community-acquired pneumonia. Respirology 2008, 13:731-735.
16. Fine M.J., Auble T.E., Yealy D.M., Hanusa B.H., Weissfeld L.A., Singer D.E., et al. Aprediction rule to identify low-risk patients with community-acquired pneumonia. NEngl J Med 1997, 336:243-250.
17. World Health Organization Collaborating Centre for Drug Statistics Methodology Guidelines for ATC classification and DDD assignment, 2012 2011, WHO, Oslo, Available from:. http://www.whocc.no/atc_ddd_index/.
18. Chastre J., Wunderink R., Prokocimer P., Lee M., Kaniga K., Friedland I. Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study. Crit Care Med 2008, 36:1089-1096.
19. Rea-Neto A., Niederman M., Lobo S.M., Schroeder E., Lee M., Kaniga K., et al. Efficacy and safety of doripenem versus piperacillin/tazobactam in nosocomial pneumonia: a randomized, open-label, multicenter study. Curr Med Res Opin 2008, 24:2113-2126.
20. Kollef M.H., Chastre J., Clavel M., Restrepo M.I., Michiels B., Kaniga K., et al. Arandomized trial of 7-day doripenem versus 10-day imipenem-cilastatin for ventilator-associated pneumonia. Crit Care 2012, 16:R218.
21. Bartoloni A., Strohmeyer M., Corti G., Buonomini M.I., Franchino L., Romanelli G., et al. Multicenter randomized trial comparing meropenem (1.5 g daily) and imipenem/cilastatin (2 g daily) in the hospital treatment of community-acquired pneumonia. Drugs Exp Clin Res 1999, 25:243-252.
22. Yamamoto Y., Izumikawa K., Morinaga Y., Nakamura S., Kurihara S., Imamura Y., et al. Prospective randomized comparison study of piperacillin/tazobactam and meropenem for healthcare-associated pneumonia in Japan. JInfect Chemother 2013, 19:291-298.
23. Karino F., Miura K., Fuchita H., Koba N., Nishikawa E., Hotta T., et al. Efficacy and safety of piperacillin/tazobactam versus biapenem in late elderly patients with nursing- and healthcare-associated pneumonia. JInfect Chemother 2013, 19:909-915.
24. Lin M.Y., Lyles-Banks R.D., Lolans K., Hines D.W., Spear J.B., Petrak R., et al. The importance of long-term acute care hospitals in the regional epidemiology of Klebsiella pneumoniae carbapenemase-producing Enterobacteriaceae. Clin Infect Dis 2013, 57:1246-1252.
25. Jain A., Hopkins K.L., Turton J., Doumith M., Hill R., Loy R., et al. NDM carbapenemases in the United Kingdom: an analysis of the first 250 cases. JAntimicrob Chemother 2014, 69:1777-1784.
26. Nau R., Sorgel F., Eiffert H. Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections. Clin Microbiol Rev 2010, 23:858-883.
27. Nalda-Molina R., Dokoumetzidis A., Charkoftaki G., Dimaraki E., Margetis K., Archontaki H., et al. Pharmacokinetics of doripenem in CSF of patients with non-inflamed meninges. JAntimicrob Chemother 2012, 67:1722-1729.
28. Kollef M.H., Morrow L.E., Baughman R.P., Craven D.E., McGowan J.E., Micek S.T., et al. Health care-associated pneumonia (HCAP): a critical appraisal to improve identification, management, and outcomes-proceedings of the HCAP Summit. Clin Infect Dis 2008, 46(Suppl 4). S296-334; quiz 5-8.
29. Kohno S., Imamura Y., Shindo Y., Seki M., Ishida T., Teramoto S., et al. Clinical practice guidelines for nursing- and healthcare-associated pneumonia (NHCAP) [complete translation]. Respir Investig 2013, 51:103-126.
30. Chalmers J.D., Taylor J.K., Singanayagam A., Fleming G.B., Akram A.R., Mandal P., et al. Epidemiology, antibiotic therapy, and clinical outcomes in health care-associated pneumonia: a UK cohort study. Clin Infect Dis 2011, 53:107-113.
31. Attridge R.T., Frei C.R., Restrepo M.I., Lawson K.A., Ryan L., Pugh M.J., et al. Guideline-concordant therapy and outcomes in healthcare-associated pneumonia. Eur Respir J 2011, 38:878-887.
32. Troitino A.X., Porhomayon J., El-Solh A.A. Guideline-concordant antimicrobial therapy for healthcare-associated pneumonia: a systematic review and meta-analysis. Lung 2013, 191:229-237.
33. Carratala J., Roson B., Fernandez-Sevilla A., Alcaide F., Gudiol F. Bacteremic pneumonia in neutropenic patients with cancer: causes, empirical antibiotic therapy, and outcome. Arch Intern Med 1998, 158:868-872.
34. Lee N.Y., Lee C.C., Huang W.H., Tsui K.C., Hsueh P.R., Ko W.C. Cefepime therapy for monomicrobial bacteremia caused by cefepime-susceptible extended-spectrum beta-lactamase-producing Enterobacteriaceae: MIC matters. Clin Infect Dis 2013, 56:488-495.
35. Takahashi N., Kikutani T., Tamura F., Groher M., Kuboki T. Videoendoscopic assessment of swallowing function to predict the future incidence of pneumonia of the elderly. JOral Rehabil 2012, 39:429-437.
36. Martino R., Foley N., Bhogal S., Diamant N., Speechley M., Teasell R. Dysphagia after stroke: incidence, diagnosis, and pulmonary complications. Stroke 2005, 36:2756-2763.
37. Pikus L., Levine M.S., Yang Y.X., Rubesin S.E., Katzka D.A., Laufer I., et al. Videofluoroscopic studies of swallowing dysfunction and the relative risk of pneumonia. AJR Am J Roentgenol 2003, 180:1613-1616.
38. Holas M.A., DePippo K.L., Reding M.J. Aspiration and relative risk of medical complications following stroke. Arch Neurol 1994, 51:1051-1053.
39. Titsworth W.L., Abram J., Fullerton A., Hester J., Guin P., Waters M.F., et al. Prospective quality initiative to maximize dysphagia screening reduces hospital-acquired pneumonia prevalence in patients with stroke. Stroke 2013, 44:3154-3160.
40. Kadowaki M., Demura Y., Mizuno S., Uesaka D., Ameshima S., Miyamori I., et al. Reappraisal of clindamycin IV monotherapy for treatment of mild-to-moderate aspiration pneumonia in elderly patients. Chest 2005, 127:1276-1282.